Biogen BIIB Biosimilars — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's biosimilars — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's biosimilars — total revenue?
- Biogen (BIIB) reported biosimilars — total revenue of $182.2M in Q1 2026.
- How has Biogen's biosimilars — total revenue changed year-over-year?
- Biogen's biosimilars — total revenue increased by 0.8% year-over-year, from $180.8M to $182.2M.
- What is the long-term trend for Biogen's biosimilars — total revenue?
- Over 4 years (2021 to 2025), Biogen's biosimilars — total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $831.2M to $729.1M.
- What does biosimilars — total revenue mean?
- This metric represents the total gross revenue generated from the sale of biosimilar pharmaceutical products within the company's portfolio. It reflects the commercial success and market penetration of therapeutic products that are highly similar to already approved reference biologic drugs. This revenue stream is a key indicator of the company's ability to compete in the off-patent biologic market and diversify its income beyond proprietary specialty medicines.